Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy

Journal of Hepatology

Volumn 50, Issue 5, 2009, Pages 895-905

  Chen, Li ^a   Zhang, Qian ^b   Yu, De min ^a   Wan, Mo bin ^b   Zhang, Xin xin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Evolution; Genetic heterogeneity; Hepatitis B virus; Lamivudine; Treatment outcome

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ISOLATION; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPECIES DIVERSITY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHYLOGENY; RNA-DIRECTED DNA POLYMERASE; TREATMENT OUTCOME;

EID: 64549125990     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.018     Document Type: Article

References (35)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
3. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
4. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
5. Domingo E., and Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res 127 (2007) 131-150
6. Domingo E. Quasispecies and the development of new antiviral strategies. Prog Drug Res 60 (2003) 133-158
7. Pallier C., Castéra L., Soulier A., Hézode C., Nordmann P., Dhumeaux D., et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80 (2006) 643-653
8. Villet S., Pichoud C., Villeneuve J.P., Trepo C., and Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
9. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
10. Lim S.G., Cheng Y., Guindon S., Seet B.L., Lee L.Y., Hu P., et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 133 (2007) 951-958
11. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
12. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
13. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
14. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134 (2008) 405-415
15. Learn Jr. G.H., Korber B.T., Foley B., Hahn B.H., Wolinsky S.M., and Mullins J.I. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol 70 (1996) 5720-5730
16. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25 (1997) 4876-4882
17. Martin D., and Rybicki E. RDP: detection of recombination amongst aligned sequences. Bioinformatics 16 (2000) 562-563
18. Myers R., Clark C., Khan A., Kellam P., and Tedder R. Genotyping hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol 87 (2006) 1459-1464
19. Domingo E., Martin V., Perales C., Grande-Perez A., Garcia-Arriaza J., and Arias A. Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 299 (2006) 51-82
20. Tamura K., Dudley J., Nei M., and Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4. Mol Biol Evol 24 (2007) 1596-1599
21. Guindon S., Lethiec F., Duroux P., and Gascuel O. PHYML online - a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res 33 (2005) W557-W559
22. Posada D. ModelTest Server: a web-based tool for the statistical selection of models of nucleotide substitution online. Nucleic Acids Res 34 (2006) W700-W703
23. Rodrigo A.G., Goode M., Forsberg R., Ross H.A., and Drummond A. Inferring evolutionary rates using serially sampled sequences from several populations. Mol Biol Evol 20 (2003) 2010-2018
24. Okada S., Akahane Y., Suzuki H., Okamoto H., and Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16 (1992) 619-624
25. Chambers T.J., Fan X., Droll D.A., Hembrador E., Slater T., Nickells M.W., et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79 (2005) 3071-3083
26. Hino K., Yamaguchi Y., Fujiwara D., Katoh Y., Korenaga M., Okazaki M., et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 7 (2000) 36-42
27. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N., Marumo F., et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22 (1995) 30-35
28. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99 (2002) 3081-3086
29. Lewin S.R., Ribeiro R.M., Walters T., Lau G.K., Bowden S., Locarnini S., et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34 (2001) 1012-1020
30. Wolters L.M., Hansen B.E., Niesters H.G., and de Man R.A. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 14 (2002) 1007-1011
31. Wolters L.M., Hansen B.E., Niesters H.G., Zeuzem S., Schalm S.W., and de Man R.A. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 22 (2002) 121-126
32. Buti M., Sanchez F., Cotrina M., Jardi R., Rodriguez F., Esteban R., et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 183 (2001) 1277-1280
33. Chang M.L., Chien R.N., Yeh C.T., and Liaw Y.F. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 43 (2005) 72-77
34. Yuen M.F., Fong D.Y., Wong D.K., Yuen J.C., Fung J., and Lai C.L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46 (2007) 1695-1703
35. Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897